Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM24 + Atezolizumab in Advanced EGFR-expressing Cancers
NCT05109442Phase 2Terminated
- Sponsor
- Affimed
- Start
- Nov 2021
- Primary completion
- Mar 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of AFM24 in non-small cell lung cancer (NSCLC), gastric cancer (GC), gastroesophageal junction adenocarcinoma, pancreatic cancer (PC), hepatocellular carcinoma (HCC), sponsored by Affimed. Started Nov 2021; status: terminated.
02
Drugs
AFM24
03
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)gastroesophageal junction adenocarcinomapancreatic cancer (PC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05109442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109442.